SCHUCHERT JOSEPH S

Form 4

December 22, 2005

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB Number:

3235-0287

0.5

if no longer

January 31, Expires: 2005 Estimated average

OMB APPROVAL

subject to Section 16. Form 4 or Form 5

Check this box

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF **SECURITIES**

burden hours per response...

obligations may continue.

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

See Instruction

1(b).

(Print or Type Responses)

1. Name and Address of Reporting Person *

NICKELL FRANK T

2. Issuer Name and Ticker or Trading

Symbol

ENDO PHARMACEUTICALS

5. Relationship of Reporting Person(s) to

(Check all applicable)

Issuer

below)

HOLDINGS INC [ENDP]

3. Date of Earliest Transaction

Director X__ 10% Owner Other (specify Officer (give title

C/O KELSO & COMPANY, 320

(Street)

(State)

(First)

(Middle)

(Zip)

PARK AVENUE

(Last)

(City)

4. If Amendment, Date Original

Filed(Month/Day/Year)

(Month/Day/Year)

12/21/2005

6. Individual or Joint/Group Filing(Check

Applicable Line)

Form filed by One Reporting Person _X_ Form filed by More than One Reporting

Person

NEW YORK, NY 10022

1. Title of 2. Transaction Date 2A. Deemed Security (Month/Day/Year) Execution Date, if (Instr. 3) (Month/Day/Year)

4. Securities Acquired 3. Transaction(A) or Disposed of (D) Code (Instr. 3, 4 and 5) (Instr. 8)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned 5. Amount of 6. Ownership 7. Nature of Securities Form: Direct Indirect Beneficially (D) or Beneficial Indirect (I) Ownership Owned (Instr. 4) Following (Instr. 4)

I

Reported (A) or

Transaction(s) (Instr. 3 and 4)

Price Code V Amount (D)

by Endo

(9-02)

Common

Stock, par 12/21/2005 value \$.01

X 238,942 D \$3 15,610,119

Pharma LLC (2) (3)

per share (1)

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of SEC 1474 information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

1

Edgar Filing: SCHUCHERT JOSEPH S - Form 4

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transactic Code (Instr. 8)	5. Number of orDerivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount Underlying Securitie (Instr. 3 and 4)	
				Code V		Date Exercisable	Expiration Date	Title	Amou Numb Shares
Call Obligation (obligation to sell)	\$ 3	12/21/2005		X	238,942	11/29/2004	08/26/2007	Common Stock	238,9

Reporting Owners

Reporting Owner Name / Address	Relationships					
	Director	10% Owner	Officer	Other		
NICKELL FRANK T C/O KELSO & COMPANY 320 PARK AVENUE NEW YORK, NY 10022		X				
BERNEY PHILIP E C/O KELSO & COMPANY 320 PARK AVENUE NEW YORK, NY 10022		X				
BYNUM FRANK K C/O KELSO & COMPANY 320 PARK AVENUE NEW YORK, NY 10022		X				
GOLDBERG MICHAEL B C/O KELSO & COMPANY 320 PARK AVENUE NEW YORK, NY 10022	X	X				
Loverro Frank J C/O KELSO & COMPANY 320 PARK AVENUE NEW YORK, NY 10022	X	X				
MATELICH GEORGE E C/O KELSO & COMPANY 320 PARK AVENUE NEW YORK, NY 10022		X				
SCHUCHERT JOSEPH S C/O KELSO & COMPANY 320 PARK AVENUE NEW YORK, NY 10022		X				
WAHRHAFTIG DAVID I C/O KELSO & COMPANY 320 PARK AVENUE	X	X				

Reporting Owners 2

NEW YORK, NY 10022

WALL THOMAS R IV

C/O KELSO & COMPANY 320 PARK AVENUE X

NEW YORK, NY 10022

Connors James J II

C/O KELSO & COMPANY 320 PARK AVENUE X

NEW YORK, NY 10022

Signatures

/s/James J. Connors, II 12/22/2005

> **Signature of Reporting Person Date

James J. Connors, II by Power of

11/08/2005 Attorney

> **Signature of Reporting Person Date

James J. Connors, II by Power of 11/09/2005

Attorney **Signature of Reporting Person Date

James J. Connors, II by Power of

11/08/2005 Attorney

**Signature of Reporting Person

Date

James J. Connors, II by Power of 11/08/2005 Attorney

**Signature of Reporting Person Date

James J. Connors, II by Power of

11/08/2005 Attorney

**Signature of Reporting Person Date

James J. Connors, II by Power of 11/08/2005

Attorney

**Signature of Reporting Person Date

James J. Connors, II by Power of 11/08/2005

Attorney

**Signature of Reporting Person Date

James J. Connors, II by Power of 11/08/2005

Attorney

**Signature of Reporting Person Date

James J. Connors, II by Power of 11/08/2005

Attorney

**Signature of Reporting Person Date

Explanation of Responses:

- If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

(1) Kelso Partners V, L.P. (KP V") is the designated filer.

Signatures 3

Edgar Filing: SCHUCHERT JOSEPH S - Form 4

- KP V may be deemed to share beneficial ownership of shares of Common Stock owned of record by Endo Pharma LLC by virtue of its status as a member of Endo Pharma LLC. KP V shares investment and voting power along with the other members of Endo Pharma LLC with respect to securities owned by Endo Pharma LLC, but disclaims beneficial ownership of such securities except to the extent of its pecuniary interest.
- Each individual reporting person may be deemed to share beneficial ownership of shares of Common Stock owned of record by KP V, by virtue of his status as a general partner of the general partner of KP V, and each individual shares investment and voting power along with the other general partners of KP V, but disclaims beneficial ownership of such securities except to the extent of his pecuriary interest.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.